上海专家团队自研试剂，为胰腺癌精准医疗贡献“中国方案”

Core Viewpoint - The "Human Pancreatic Cancer 6 Gene Mutation Detection Kit," developed by Professor Yu Xianjun's team at Fudan University Affiliated Tumor Hospital, has been officially registered with the Shanghai Municipal Drug Administration, marking it as the first self-developed in vitro diagnostic reagent for pancreatic cancer in China and the world [1][3]. Group 1: Product Development and Approval - The detection kit is the first of its kind to be approved for use by a medical institution in China, contributing to global precision medicine for pancreatic cancer [1][3]. - The kit addresses the urgent need for effective gene testing methods in clinical settings, particularly for pancreatic cancer patients who often miss surgical opportunities due to late diagnosis [3][4]. Group 2: Clinical Significance and Technology - Pancreatic cancer is known for its high malignancy and rapid progression, with most patients diagnosed at advanced stages, leading to low five-year survival rates [3]. - Traditional gene testing methods are limited in scope and sensitivity, often missing critical mutations, which can hinder personalized treatment plans [3][4]. - The new kit integrates next-generation sequencing technology and ultra-deep capture techniques, significantly improving mutation detection rates and providing a comprehensive view of gene variations for personalized treatment [6]. Group 3: Research and Development Team - A cross-disciplinary research team was formed to focus on the molecular characteristics of pancreatic cancer in the Chinese population, led by Professor Hu Xin from the Precision Tumor Center at Fudan University Affiliated Tumor Hospital [4]. - The team has spent three years overcoming key technical challenges to achieve breakthroughs in precision and efficiency in mutation detection [6].